Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

PURPOSE: There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2012
Onderwerpen:
Original Reports
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675689/
https://ncbi.nlm.nih.gov/pubmed/22025146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.5040
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items